Medical Therapy of Gastro-Oesophageal Reflux Disease


Proton Pump Inhibitor Acid Suppression Proton Pump Inhibitor Therapy Lower Oesophageal Sphincter Functional Heartburn 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Adachi K, Katsube T, Kawamura A et al (2000) CYP 2C19 genotype status and intragastric pH during dosing with lasoprazole and rabeprazole. Aliment Pharmacol Ther 14: 1259–1266PubMedCrossRefGoogle Scholar
  2. [2]
    Armstrong D, Marshall JK, Chiba N et al (2004) Canadian consensus conference on the management of gastroesophageal reflux disease in adults — update 2004. Can J Gastroenterol 19: 15–35Google Scholar
  3. [3]
    Armstrong D, Talley NJ, Lauritsen K et al (2004) The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomperazole and omeprazole. Aliment Pharmacol Ther 20: 413–436PubMedCrossRefGoogle Scholar
  4. [4]
    Armstrong D, Veldhuizenvan Zanten SJO, Barkun AN et al (2005) Heartburn-dominant, univestigated dyspepsia: a comparison of “PPI-start” and “H2-RA-start” management strategy in primary care — the CADETHR study. Aliment Pharmacol Ther 21: 1189–1202PubMedCrossRefGoogle Scholar
  5. [5]
    Blum AL, Martinek J (1999) Interactions of proton pump inhibitors and Helicobacter pylori in vivo. In: Proton pump inhibitors (Olbe L, ed). Basel Boston London: Birkhäuser, pp 130–141Google Scholar
  6. [6]
    Caro JJ, Salas M, Ward A (2001) Healing and relapse rates in gastroesophageal reflux disease treated with newer proton pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 23: 998–1017PubMedCrossRefGoogle Scholar
  7. [7]
    Cantu P, Carmagnola S, Savojardo D, Aloca M, Penagini R (2003) Effect of non-selective gamma-aminobutyric acid receptor stimulation on motor function of the lower oesophageal sphincter and gastro-oesophageal reflux in healthy human subjects. Aliment Pharmacol Ther 18: 699–704PubMedCrossRefGoogle Scholar
  8. [8]
    Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L (1997) Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 11: 473–482PubMedCrossRefGoogle Scholar
  9. [9]
    Ciccaglione AF, Marzio L (2003) Effect of acute and chronic administration of the GABAB agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 52: 464–470PubMedCrossRefGoogle Scholar
  10. [10]
    Chiba N, de Gara CJ, Wilkinson JM, Hunt RH (1997) Speed of healing and symptom relief in grade-II to-IV gastroesophageal reflux disease: a meta-analysis. Gastroenetrology 112: 1798–1810CrossRefGoogle Scholar
  11. [11]
    Dent J, Brun J, Fendrick AM et al (1999) An evidence-based appraisal of reflux disease management — the Genval Workshop Report. Gut 44(Suppl. 2): 1–16CrossRefGoogle Scholar
  12. [12]
    DeVault KR, Castell DO (1999) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The practice parameters committee of the American College of Gastroenterology. Am J Gastroenetrol 94: 1434–1442CrossRefGoogle Scholar
  13. [13]
    Donnellan C, Sharma N, Preston C, Moayyedi P (2005) Medical treatments for maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. Cochrane Database Syst Rev 2: CD 003245Google Scholar
  14. [14]
    Eriksson S, Langström G, Rikner L, Carlsson R, Naesdal J (1995) Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenetrol Hepatol 7: 467–475Google Scholar
  15. [15]
    Fass, R, Shapiro M, Dekel R, Sewell J (2005) Systematic review: proton pump inhibitor failure in gastro-oesophageal reflux disease — where next? Aliment Pharmacol Ther 22: 79–94PubMedCrossRefGoogle Scholar
  16. [16]
    Howden CW, Henning JM, Huang B, Lukasik N, Freston JW (2001) Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies. Am J Gastroenterol 96: 1704–1710PubMedCrossRefGoogle Scholar
  17. [17]
    Klok RM, Postma MJ, van Hout BA, Brouwers JR (2003) Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 17: 1237–1245PubMedCrossRefGoogle Scholar
  18. [18]
    Koeck GH, Sifrim D, Lerut T, Janssens J, Tack J (2003) Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52: 1397–1402CrossRefGoogle Scholar
  19. [19]
    Koop H, Katschinski M, Arnold R (1991) Konservative Behandlung der floriden peptischen Ösophagusstenose. Vollständige Beseitigung durch Bougeirung und Omeprazol bei H2-Blocker-refraktären Fällen. Med Klin 86: 566–568Google Scholar
  20. [20]
    Koop H, Schepp W, Müller-Lissner S et al (2005) Gastroösophageale Refluxkrankheit — Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten. Z Gastroenterol 43: 163–194PubMedCrossRefGoogle Scholar
  21. [21]
    Labenz J, Armstrong D, Lauritsen K et al (2005) A randomised comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagtis: the EXPO study. Aliment Pharmacol Ther 21: 739–746PubMedCrossRefGoogle Scholar
  22. [22]
    Meining A, Classen M (2000) The role of diet an lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 95: 2692–2697PubMedCrossRefGoogle Scholar
  23. [23]
    Sandvik AK, Brenna E, Waldum HL (1997) Review article: the pharmacological inhibition of acid secretion — tolerance and rebound. Aliment Pharmacol Ther 11: 1013–1018PubMedCrossRefGoogle Scholar
  24. [24]
    Sifrim D, Holloway RH, Silny J, Tack J, Lerut T, Janssens J (2001) Composition of the postprandial refluxate in patients with gastro-esophageal reflux disease. Amer J Gastroenterol 96: 647–655CrossRefGoogle Scholar
  25. [25]
    Silvis SE, Farahmand M, Johnson JA, Ansel HJ, Ho SB (1996) A randomized blinded comparison of omeprazole and ranitidine in the treatment of chronic esophageal stricture secondary to acid peptic reflux. Gastrointest Endoc 43: 216–221CrossRefGoogle Scholar
  26. [26]
    Smith PM, Kerr GD, Cockel R et al (1994) A comparison of omeprazole and ranitidine in the prevention of recurrance of benign esophageal stricture. Restore Investigator Group. Gastroenterology 107: 1545–1548Google Scholar
  27. [27]
    Thomson AB, Barkun AN, Armstrong D et al (2003) The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian Adult Dyspepsia Emperiric Therapy — Prompt Endoscopy (CADET-PE) study. Aliment Pharmacol Ther 17: 1481–1491PubMedCrossRefGoogle Scholar
  28. [28]
    Tytgat GN, Heading RC, Müller-Lissner S et al (2003) Contemporary understanding and management of reflux and constipation in the general population and pregnancy: a consensus meeting. Aliment Pharmacol Ther 18: 291–301PubMedCrossRefGoogle Scholar
  29. [29]
    van Pinxteren B, Numans ME, Bonis PA, Lau J (2004) Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux-like symptoms and endoscopy negative reflux disease. Cochrane Database Sys Rev 4: CD 002095Google Scholar
  30. [30]
    Vela MF, Tutuian R, Katz PO, Castell DO (2003) Baclofen decreases acid and non-acid post-prandial gastroesophageal reflux measured by combined multi-channel intraluminal impedance and pH. Aliment Pharmacol Ther 17: 243–251PubMedCrossRefGoogle Scholar
  31. [31]
    Vela MF, Camacho-Lubato L, Srinivasan R, Tutuian R, Katz PO, Castel DO (2001) Simultaneous intra-esophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenetrology 120: 1599–1806CrossRefGoogle Scholar
  32. [32]
    Venables TL, Newland RD, Patel AC, Hole J, Wicock C, Turbitt ML (1997) Omeprazole 10 milligrams once daily, omeprazole 20 mg once daily, or ranitidine 150 twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general pratice. Scand J Gastroenterol 32: 965–973PubMedCrossRefGoogle Scholar
  33. [33]
    Vigneri S, Termini R, Leandro G et al (1995) A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 333: 1106–1110PubMedCrossRefGoogle Scholar
  34. [34]
    Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352: 2211–2221PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 2006

Authors and Affiliations

  • H. Koop
    • 1
  1. 1.II. Innere KlinikHELIOS Klinikum Berlin-BuchBerlinGermany

Personalised recommendations